Fluorescence in situ hybridization, otherwise known as FISH testing has been utilized for many years in the assessment and stratification of plasma cell neoplasms. In this testing, our laboratory analyzes only plasma cells so that we can identify abnormalities specific to the patient's plasma cell clone. This new algorithmic approach will provide an estimated 20% reduction in unnecessary testing.

Linda Baughn Ph.D. gives an overview of this test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered and what clinical action can be taken due to the results provided.

Testing

Plasma Cell Proliferative Disorder, FISH, Bone Marrow (Mayo ID: PCPDS)

Useful for:

Aiding in the diagnosis of new cases of multiple myeloma or other plasma cell proliferative disorders and identifying prognostic markers based on the anomalies found.

Specimen Requirements

Specimen Type: Bone Marrow

Container/Tube: Yellow top (ACD)

Specimen Volume: 4 mL

Collection Instructions: Invert several times to mix bone marrow

Performance Information

Day(s) and Time(s) Test Performed 

Monday through Sunday; Varies

Analytic Time 

7 days

Additional Resources


Samantha Rossi

Samantha Rossi

Samantha Rossi is a Marketing Associate at Mayo Clinic Laboratories. She supports marketing strategies for product management and specialty testing. Samantha has worked at Mayo Clinic since 2019.